Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1997 May;76(5):405–410. doi: 10.1136/adc.76.5.405

Adrenal function and high dose inhaled corticosteroids for asthma

P Yiallouros 1, A Milner 1, E Conway 1, J Honour 1
PMCID: PMC1717181  PMID: 9196354

Abstract

Accepted 31 January 1997


OBJECTIVE—To investigate effects on adrenal function of fluticasone, a recently released inhaled steroid preparation with lower systemic bioavailability than beclomethasone dipropionate.
METHODS—34 children on high doses (400-909 µg/m2/d) of inhaled beclomethasone dipropionate or budesonide were recruited into a double blind, crossover study investigating the effects on adrenal function of beclomethasone and fluticasone propionate, given using a standard spacer (Volumatic). The 24 hour excretion rates of total cortisol and cortisol metabolites were determined at baseline (after a two week run in), after six weeks treatment with an equal dose of beclomethasone, and after six weeks of treatment with half the dose of fluticasone, both given through a spacer device.
RESULTS—The comparison of effects between fluticasone and beclomethasone during treatment periods, although favouring fluticasone in all measured variables, reached significance only after correction for urinary creatinine excretion (tetrahydrocortisol and 5α-tetrahydrocortisol geometric means: 424 v 341 µg/m2/d). The baseline data showed adrenal suppression in the children taking beclomethasone (total cortisol geometric means: 975 v 1542µg/d) and a dose related suppression in the children taking budesonide. Suppressed adrenal function in the children who were taking beclomethasone at baseline subsequently improved with fluticasone and beclomethasone during treatment periods.
CONCLUSIONS—Fluticasone is less likely to suppress adrenal function than beclomethasone at therapeutically equivalent doses. The baseline data also support the claim that spacer devices should be used for the administration of high doses of inhaled topical steroids.



Full Text

The Full Text of this article is available as a PDF (130.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes N. C., Marone G., Di Maria G. U., Visser S., Utama I., Payne S. L. A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. International Study Group. Eur Respir J. 1993 Jun;6(6):877–885. [PubMed] [Google Scholar]
  2. Bisgaard H., Damkjaer Nielsen M., Andersen B., Andersen P., Foged N., Fuglsang G., Høst A., Leth C., Pedersen M., Pelck I. Adrenal function in children with bronchial asthma treated with beclomethasone dipropionate or budesonide. J Allergy Clin Immunol. 1988 Jun;81(6):1088–1095. doi: 10.1016/0091-6749(88)90874-3. [DOI] [PubMed] [Google Scholar]
  3. Bisgaard H., Pedersen S., Damkjaer Nielsen M., Osterballe O. Adrenal function in asthmatic children treated with inhaled budesonide. Acta Paediatr Scand. 1991 Feb;80(2):213–217. doi: 10.1111/j.1651-2227.1991.tb11836.x. [DOI] [PubMed] [Google Scholar]
  4. Brown P. H., Blundell G., Greening A. P., Crompton G. K. Do large volume spacer devices reduce the systemic effects of high dose inhaled corticosteroids? Thorax. 1990 Oct;45(10):736–739. doi: 10.1136/thx.45.10.736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Farrer M., Francis A. J., Pearce S. J. Morning serum cortisol concentrations after 2 mg inhaled beclomethasone dipropionate in normal subjects: effect of a 750 ml spacing device. Thorax. 1990 Oct;45(10):740–742. doi: 10.1136/thx.45.10.740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Geddes D. M. Inhaled corticosteroids: benefits and risks. Thorax. 1992 Jun;47(6):404–407. doi: 10.1136/thx.47.6.404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Goldstein D. E., König P. Effect of inhaled beclomethasone dipropionate on hypothalamic-pituitary-adrenal axis function in children with asthma. Pediatrics. 1983 Jul;72(1):60–64. [PubMed] [Google Scholar]
  8. Gustafsson P., Tsanakas J., Gold M., Primhak R., Radford M., Gillies E. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 micrograms/day with inhaled beclomethasone dipropionate 400 micrograms/day in mild and moderate asthma. Arch Dis Child. 1993 Aug;69(2):206–211. doi: 10.1136/adc.69.2.206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Harding S. M. The human pharmacology of fluticasone propionate. Respir Med. 1990 Nov;84 (Suppl A):25–29. doi: 10.1016/s0954-6111(08)80004-2. [DOI] [PubMed] [Google Scholar]
  10. Honour J. W., Kelnar C. J., Brook C. G. Urine steroid excretion rates in childhood reflect growth and activity of the adrenal cortex. Acta Endocrinol (Copenh) 1991 Feb;124(2):219–224. doi: 10.1530/acta.0.1240219. [DOI] [PubMed] [Google Scholar]
  11. Klein R., Waldman D., Kershnar H., Berger W., Coulson A., Katz R. M., Rachelefsky G. S., Siegel S. C. Treatment of chronic childhood asthma with beclomethasone dipropionate aerosol: I. A double-blind crossover trial in nonsteroid-dependent patients. Pediatrics. 1977 Jul;60(1):7–13. [PubMed] [Google Scholar]
  12. Koch G. G. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics. 1972 Jun;28(2):577–584. [PubMed] [Google Scholar]
  13. Law C. M., Marchant J. L., Honour J. W., Preece M. A., Warner J. O. Nocturnal adrenal suppression in asthmatic children taking inhaled beclomethasone dipropionate. Lancet. 1986 Apr 26;1(8487):942–944. doi: 10.1016/s0140-6736(86)91045-7. [DOI] [PubMed] [Google Scholar]
  14. Newman S. P., Millar A. B., Lennard-Jones T. R., Morén F., Clarke S. W. Improvement of pressurised aerosol deposition with Nebuhaler spacer device. Thorax. 1984 Dec;39(12):935–941. doi: 10.1136/thx.39.12.935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Newman S. P., Pavia D., Morén F., Sheahan N. F., Clarke S. W. Deposition of pressurised aerosols in the human respiratory tract. Thorax. 1981 Jan;36(1):52–55. doi: 10.1136/thx.36.1.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Nicolaizik W. H., Marchant J. L., Preece M. A., Warner J. O. Endocrine and lung function in asthmatic children on inhaled corticosteroids. Am J Respir Crit Care Med. 1994 Sep;150(3):624–628. doi: 10.1164/ajrccm.150.3.8087329. [DOI] [PubMed] [Google Scholar]
  17. Pedersen S., Fuglsang G. Urine cortisol excretion in children treated with high doses of inhaled corticosteroids: a comparison of budesonide and beclomethasone. Eur Respir J. 1988 May;1(5):433–435. [PubMed] [Google Scholar]
  18. Priftis K., Everard M. L., Milner A. D. Unexpected side-effects of inhaled steroids: a case report. Eur J Pediatr. 1991 Apr;150(6):448–449. doi: 10.1007/BF02093730. [DOI] [PubMed] [Google Scholar]
  19. Priftis K., Milner A. D., Conway E., Honour J. W. Adrenal function in asthma. Arch Dis Child. 1990 Aug;65(8):838–840. doi: 10.1136/adc.65.8.838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Springer C., Avital A., Maayan C., Rosler A., Godfrey S. Comparison of budesonide and beclomethasone dipropionate for treatment of asthma. Arch Dis Child. 1987 Aug;62(8):815–819. doi: 10.1136/adc.62.8.815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Tabachnik E., Zadik Z. Diurnal cortisol secretion during therapy with inhaled beclomethasone dipropionate in children with asthma. J Pediatr. 1991 Feb;118(2):294–297. doi: 10.1016/s0022-3476(05)80506-2. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES